Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases

Bone metastases are prevalent among cancer patients and frequently cause significant morbidity. Oncology providers must mitigate complications associated with bone metastases while limiting therapy-related adverse effects and their impact on quality of life. Multiple treatment modalities, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Longo, John, Lutz, Stephen, Johnstone, Candice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746785/
https://www.ncbi.nlm.nih.gov/pubmed/23976864
http://dx.doi.org/10.2147/CMAR.S35789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746785/
https://www.ncbi.nlm.nih.gov/pubmed/23976864
http://dx.doi.org/10.2147/CMAR.S35789

Ejemplares similares